secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organogenesis Holdings Inc. (ORGO)
CIK:        0001661181
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001193125-22-146299
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organogenesis Q1 revenue down 4% to $98.1M; net income drops to $0.1M from $9.9M
--------------------------------------------------------------------------------

- Net revenue $98.1M, down 4% YoY; adjusted net income $1.2M vs $11.2M.
- Surgical & Sports Medicine revenue fell 39% to $7.2M due to ReNu/NuCel discontinuation.
- PuraPly revenue grew 29% to $53.3M, partially offsetting declines.
- Adjusted EBITDA $5.0M, down 69% from $16.0M; cash at $108.5M.
- FY2022 guidance: net revenue $485M-$515M, net income $41.2M-$52.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661181/000119312522146299/0001193125-22-146299-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661181/000119312522146299/d332410d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-146299

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer